Answers are grounded in this paper and cite their sources.
In RA patients with prior exposure to a biologic agent, exposure to etanercept, infliximab, or rituximab was associated with a greater 1-year risk of hospitalized infection compared with the risk associated with exposure to abatacept.
No takes yet. Share an insight, caveat, or question.
Yun et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: